CCO Infectious Disease Podcast

Q&A: HDV Management Episode 2

Episode Summary

In this podcast episode, listen to expert faculty perspectives on HDV management, including limitations to AASLD screening recommendations, use of double reflex testing, approaches to staging advanced liver disease, considerations for treatment, and clinical trial updates .

Episode Notes

In this episode, Tatyana Kushner, MD, MSCE, and Stefan Zeuzem, MD, address key considerations when screening, diagnosing, and treating patients with HDV, such as:

• Barriers to HDV screening, including limitations to AASLD guideline recommendations
• Use of double reflex testing to improve HDV diagnosis
• Considerations for repeat HDV testing in patients who are HBsAg positive who previously tested negative for HDV
• Updated CDC recommendations for HBV screening for all adults using a triple panel test 
• Staging advanced liver disease in patients with HDV
• Indications for HDV treatment, including patients with low ALT levels and advanced or progressive liver disease
• Treatment landscape for HDV
• Personal experiences with use of pegylated interferon for HDV treatment, including considerations for use in patients with compensated cirrhosis
• Updates on novel HDV therapies, including:
  • Summary of efficacy data on bulevirtide from clinical trials
  • Interpretation of results from D-LIVR, a phase III trial assessing the safety and efficacy of lonafarnib 

Link to full program: 
bit.ly/3yp1Lxf